| Literature DB >> 31113390 |
Zhuo Yang1, Wenzhe Zhou2, Quexuan Cui2, Ling Qiu1, Bing Han3.
Abstract
BACKGROUND: Southern China provinces have high incidence of thalassemia, however, sporadic cases can be found in northern China as well.Entities:
Keywords: Altitude; China; Gene mutation; Spectrum; Thalassemia
Mesh:
Year: 2019 PMID: 31113390 PMCID: PMC6530100 DOI: 10.1186/s12881-019-0818-7
Source DB: PubMed Journal: BMC Med Genet ISSN: 1471-2350 Impact factor: 2.103
Demographic data of the patients enrolled
| Demographic Data | Individuals only with α-thalassemia | Individuals only with β-thalassemia | Individuals combined α−/β-thalassemia carriers | |
|---|---|---|---|---|
| Total | 1059 | 359 | 683 | 17 |
| Sex distribution | ||||
| males | 299 (28.2) | 116 (32.3) | 177 (25.9) | 6 (35.3) |
| females | 760 (71.8) | 243 (67.7) | 506 (74.1) | 11 (64.7) |
| Age distribution | ||||
| 0–10 | 89 (8.4) | 28 (7.8) | 61 (8.9) | – |
| 11–20 | 40 (3.8) | 12 (3.3) | 28 (4.1) | 9 (52.9) |
| 21–30 | 443 (41.8) | 154 (42.9) | 280 (41.0) | 7 (41.2) |
| 31–40 | 372 (35.1) | 133 (37.0) | 232 (34.0) | 1 (5.9) |
| 41–50 | 56 (5.3) | 16 (4.5) | 39 (5.7) | – |
| >50 | 59 (5.6) | 16 (4.5) | 43 (6.3) | – |
| Geographic distribution | ||||
| Northern region of China | 183 (17.3) | 42 (11.7) | 140 (20.5) | 1 (5.9) |
| Southern region of China | 876 (82.7) | 317 (88.3) | 543 (79.5) | 16 (94.1) |
Table Legend: N = number of patients; % = number of events/total number of patients in column*100
Frequency and distribution of α and β thalassemia mutations
| Mutation | Type | Northern region | Southern region | Overall distribution in China | |||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| α-thalassemia | |||||||
| Total | 49 | 100.0% | 356 | 100.0% | 405 | 100.0% | |
| NG_000006.1:g.26264_45564del19301 | α0 | 35 | 71.4% | 268 | 75.2% | 303 | 74.8% |
| NG_000006.1:g.34164_37967del3804 | α+ | 12 | 24.5% | 53 | 14.9% | 65 | 16.1% |
| -α4.2 | α+ | 2 | 4.1% | 20 | 5.6% | 22 | 5.4% |
| HBA2:c.427 T > C | α+ | – | – | 7 | 2.0% | 7 | 1.7% |
| HBA2:c.377 T > C | α+ | – | – | 5 | 1.4% | 5 | 1.2% |
| HBA2:c.369C > G | α+ | – | – | 3 | 0.9% | 3 | 0.7% |
| χ2 test | χ2 = 2.582, p = 0.275 | ||||||
| β-thalassemia | |||||||
| Total | 131 | 100.0% | 541 | 100.0% | 672 | 100.0% | |
| HBB:c.316-197C > T | β0 | 52 | 39.7% | 195 | 36.0% | 247 | 36.8% |
| HBB:c.126_129 delCTTT | β0 | 33 | 25.2% | 157 | 29.0% | 190 | 28.3% |
| HBB:c.52A > T | β0 | 35 | 26.7% | 134 | 24.8% | 169 | 25.3% |
| HBB:c.-78A > G | β0 | 2 | 1.5% | 18 | 3.3% | 20 | 3.0% |
| HBB:c.216_217insA | β+ | 3 | 2.3% | 16 | 3.0% | 19 | 2.8% |
| HBB:c.84_85insC | β+ | 1 | 0.8% | 6 | 1.1% | 7 | 1.0% |
| HBB:c.130G > T | β0 | 1 | 0.8% | 6 | 1.1% | 7 | 1.0% |
| HBB:c.79G > T | βE | 2 | 1.5% | 4 | 0.7% | 6 | 0.9% |
| HBB:c.-79A > G | β0 | 1 | 0.8% | 3 | 0.6% | 4 | 0.6% |
| HBB:c.45_46insG | β+ | – | – | 1 | 0.2% | 1 | 0.1% |
| HBB:c.92 + 1G > T | β0 | – | – | 1 | 0.2% | 1 | 0.1% |
| HBB:c.92 + 5G > C | β+ | 1 | 0.8% | – | – | 1 | 0.1% |
| χ2 test | χ2 = 2.409, p = 0.661 | ||||||
Table Legend: N = number of patients, % number of events/total number of patients*100; p-value for the χ2 test are performed. Significant differences (p < 0.05) are highlighted in grey
Fig. 1Spectrum of α and β thalassemia mutations in Northern population origin from Southern and Northern region.(a) Frequency of 6 most common α mutations composed the columns, spectrum of α thalassemia mutations origin from southern and northern area is present separately. (b) Frequency of 6 most common β mutations composed the columns, spectrum of β thalassemia mutations origin from southern and northern area is present separately. All precise value of each mutation are shown in Table 3 and Table 4
Frequency and distribution of α and β thalassemia mutations in Northern Chinese provinces
| Mutation | Type | Beijing | Tianjin | Hebei | Shanxi | Inner Mongolia | Shandong | Henan | Shaanxi | Gansu | Xinjiang | Liaoning | Jilin | Heilong jiang |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| α-thalassemia | ||||||||||||||
| N (total) | 15 | 1 | 10 | – | 6 | 5 | 6 | 1 | – | – | 2 | 1 | 2 | |
| NG_000006.1:g.26264_45564del19301 | α0 | 73.3% | 100.0% | 60.0% | – | 66.7% | 80.0% | 83.3% | 100.0% | – | – | 50.0% | – | 100.0% |
| NG_000006.1:g.34164_37967del3804 | α+ | 20.0% | – | 40.0% | – | 33.3% | 20.0% | 16.7% | – | – | – | – | 100.0% | – |
| -α4.2 | α+ | 6.7% | – | – | – | – | – | – | – | – | – | 50.0% | – | – |
| β-thalassemia | ||||||||||||||
| N (total) | 36 | 6 | 26 | 10 | 3 | 11 | 12 | 9 | 4 | 1 | 6 | 4 | 3 | |
| HBB:c.316–197 C > T | β0 | 36.1% | 33.3% | 38.5% | 70.0% | 33.3% | 72.7% | 50.0% | 22.2% | – | – | 16.7% | 50.0% | – |
| HBB:c.126_129 delCTTT | β0 | 36.1% | 33.3% | 23.1% | 10.0% | – | 9.1% | 16.7% | 44.4% | 25.0% | – | 16.7% | – | 66.7% |
| HBB:c.52A > T | β0 | 22.2% | 16.7% | 30.8% | 20.0% | 33.33% | 9.1% | 25.0% | 22.2% | 75.0% | 100.0% | 50.0% | 50.0% | – |
| HBB:c.-78A > G | β0 | – | 16.7% | – | – | – | 9.1% | – | – | – | – | – | – | – |
| HBB:c.216_217 insA | β+ | 2.8% | – | – | – | 33.3% | – | 8.3% | – | – | – | – | – | – |
| HBB:c.84_85insC | β+ | – | – | 3.8% | – | – | – | – | – | – | – | – | – | – |
| HBB:c.130G > T | β0 | – | – | – | – | – | – | – | – | – | – | – | – | 33.3% |
| HBB:c.79G > T | βE | 2.8% | – | – | – | – | – | – | 11.1% | – | – | – | – | – |
| HBB:c.-79A > G | β0 | – | – | – | – | – | – | – | – | – | – | 16.7% | – | – |
| HBB:c.92 + 5G > C | β+ | – | – | 3.8% | – | – | – | – | – | – | – | – | – | – |
Table Legend: N Number of patients; % number of events/total number of patients*100
Frequency and distribution of α and β thalassemia mutations in Southern Chinese provinces during 2012–2017
| Mutation | Type | Shang hai | Zhe jiang | Jiangsu | Anhui | Fujian | Jiangxi | Hubei | Hunan | Chong qing | Sichuan | Guizhou | Yunnan | Guang dong | Guangxi | Hainan |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| α-thalassemia | ||||||||||||||||
| N (total) | 3 | 14 | 6 | 12 | 40 | 45 | 26 | 32 | 4 | 43 | 6 | 4 | 33 | 83 | 5 | |
| NG_000006.1:g.26264_45564del19301 | α0 | 66.7% | 57.1% | 83.3% | 75.0% | 70.0% | 84.4% | 76.9% | 81.3% | 75.0% | 76.7% | 66.7% | 75.0% | 84.9% | 69.9% | 60.0% |
| NG_000006.1:g.34164_37967del3804 | α+ | 33.3% | 28.6% | – | 16.7% | 22.5% | 11.1% | 11.5% | 12.5% | – | 11.6% | 16.7% | 25.0% | 9.1% | 15.7% | 40.0% |
| -α4.2 | α+ | – | – | – | 8.3% | – | 2.2% | 7.7% | 3.1% | 25.0% | 11.6% | – | – | 3.0% | 9.6% | – |
| HBA2:c.427 T > C | α+ | – | – | – | – | – | 2.2% | – | 3.1% | – | – | 16.7% | – | 3.0% | 3.6% | – |
| HBA2:c.377 T > C | α+ | – | – | 16.67% | – | 5.0% | – | 3.9% | – | – | – | – | – | – | 1.2% | – |
| HBA2:c.369C > G | α+ | – | 14.3% | – | – | 2.5% | – | – | – | – | – | – | – | – | – | – |
| β-thalassemia | ||||||||||||||||
| N (total) | 3 | 23 | 12 | 18 | 29 | 45 | 71 | 79 | 15 | 112 | 18 | 6 | 35 | 66 | 9 | |
| HBB:c.316–197 C > T | β0 | 100.0% | 39.1% | 16.7% | 44.4% | 51.7% | 57.8% | 56.3% | 41.8% | 40.0% | 28.6% | 22.2% | 33.3% | 25.7% | 6.1% | 22.2% |
| HBB:c.126_129 delCTTT | β0 | – | 21.7% | 25.0% | 16.7% | 34.5% | 26.7% | 25.4% | 22.8% | 46.7% | 20.5% | 50.0% | 16.7% | 42.9% | 42.4% | 55.6% |
| HBB:c.52A > T | β0 | – | 26.1% | 33.3% | 33.3% | 10.3% | 4.4% | 11.3% | 16.5% | 13.3% | 47.3% | 27.8% | 33.3% | 17.1% | 36.4% | – |
| HBB:c.-78A > G | β0 | – | 8.7% | – | – | – | 6.7% | 2.8% | 1.3% | – | 0.9% | – | – | 8.6% | 9.1% | – |
| HBB:c.216_217 insA | β+ | – | – | 25.0% | – | – | – | 1.4% | 7.6% | – | 0.9% | – | – | – | 6.1% | 11.1% |
| HBB:c.84_85insC | β+ | – | 4.4% | – | 5.6% | 3.5% | 2.2% | 1.4% | – | – | 0.9% | – | – | – | – | – |
| HBB:c.130G > T | β0 | – | – | – | – | – | 2.2% | 1.4% | 3.8% | – | 0.9% | – | – | – | – | – |
| HBB:c.79G > T | βE | – | – | – | – | – | – | – | 2.5% | – | – | – | 16.7% | – | – | 11.1% |
| HBB:c.-79A > G | β0 | – | – | – | – | – | – | – | 1.3% | – | – | – | – | 5.7% | – | – |
| HBB:c.45_46insG | β+ | – | – | – | – | – | – | – | 1.3% | – | – | – | – | – | – | – |
| HBB:c.92 + 5G > C | β0 | – | – | – | – | – | – | – | 1.3% | – | – | – | – | – | – | – |
Table Legend: N Number of patients, % Number of events/total number of patients*100
Frequency and distribution of α and β thalassemia mutations according to different elevation
| Mutation | Type | Plain area | Mountain range | Continental plateau | Overall distribution in China | ||||
|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % | ||
| α-thalassemia | |||||||||
| Total | 236 | 100.0% | 116 | 100.0% | 53 | 100.0% | 405 | 100.0% | |
| NG_000006.1:g.26264_45564del19301 | α0 | 181 | 75.1% | 82 | 74.0% | 40 | 75.5% | 303 | 74.8% |
| NG_000006.1:g.34164_37967del3804 | α+ | 38 | 17.8% | 19 | 13.4% | 8 | 15.1% | 65 | 16.1% |
| -α4.2 | α+ | 7 | 3.1% | 10 | 7.9% | 5 | 9.4% | 22 | 5.4% |
| HBA2:c.427 T > C | α+ | 3 | 0.9% | 4 | 3.9% | – | – | 7 | 1.7% |
| HBA2:c.377 T > C | α+ | 4 | 1.8% | 1 | 0.8% | – | – | 5 | 1.2% |
| HBA2:c.369C > G | α+ | 3 | 1.3% | – | – | – | – | 3 | 0.7% |
| χ2 test | χ2 = 5.53, | ||||||||
| χ2 = 0.11, | |||||||||
| χ2 = 4.20, | |||||||||
| β-thalassemia | |||||||||
| Total | 380 | 100.0% | 166 | 100.0% | 126 | 100.0% | 672 | 100.0% | |
| HBB:c.316-197C > T | β0 | 174 | 45.8% | 38 | 22.9% | 35 | 27.8% | 247 | 36.8% |
| HBB:c.126_129 delCTTT | β0 | 96 | 25.3% | 69 | 41.6% | 25 | 19.8% | 190 | 28.3% |
| HBB:c.52A > T | β0 | 66 | 17.4% | 43 | 25.9% | 60 | 47.6% | 169 | 25.2% |
| HBB:c.-78A > G | β0 | 13 | 3.4% | 6 | 3.6% | 1 | 0.8% | 20 | 3.0% |
| HBB:c.216_217insA | β+ | 11 | 2.9% | 6 | 3.6% | 2 | 1.6% | 19 | 2.8% |
| HBB:c.84_85insC | β+ | 6 | 1.6% | – | – | 1 | 0.8% | 7 | 1.0% |
| HBB:c.130G > T | β0 | 5 | 1.3% | 1 | 0.6% | 1 | 0.8% | 7 | 1.0% |
| HBB:c.79G > T | βE | 2 | 0.5% | 3 | 1.8% | 1 | 0.8% | 6 | 0.9% |
| HBB:c.-79A > G | β0 | 4 | 1.1% | – | – | – | – | 4 | 0.6% |
| HBB:c.45_46insG | β+ | 1 | 0.3% | – | – | – | – | 1 | 0.1% |
| HBB:c.92 + 1G > T | β0 | 1 | 0.3% | – | – | – | – | 1 | 0.1% |
| HBB:c.92 + 5G > C | β+ | 1 | 0.3% | – | – | – | – | 1 | 0.1% |
| χ2 test | χ2 = 29.74, | ||||||||
| χ2 = 24.21, | |||||||||
| χ2 = 45.59, | |||||||||
Table Legend: N Number of patients, % number of events/total number of patients*100, p-value for the χ2 test, plain area: provinces with elevation below 500 m; mountain range: mountain region with an altitude about 500–1000 m; Continental plateau: provinces with altitude above 1000 m